Next Meetings

May 23, 2019 9am- 5pm CT

Hyatt Regency O’Hare
LAX Room
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review evidence on esketamine as a therapy for treatment-resistant depression. The Council will also review a report on siponimod for treatment of secondary progressive MS during this meeting.

Register

Multiple Sclerosis

Midwest CEPAC
May 23, 2019 9am-5pm CT

Hyatt Regency O’Hare
LAX Room
9300 Bryn Mawr Avenue
Rosemont, IL 60018

The Midwest CEPAC will convene to review ICER's assessment of siponimod (Novartis) for secondary progressive multiple sclerosis.


June 11, 2019 10AM-4PM

California Endowment Oakland Conference Center
2000 Franklin St.
Oakland, CA 94612

CTAF will convene to review ICER's assessment of treatments for peanut allergy.


Duchenne Muscular Dystrophy

New England CEPAC
July 25, 2019 10am-4pm ET

MIT Samberg Conference Center
Salon I/T
50 Memorial Drive
Cambridge, MA 02142

The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for Duchenne muscular dystrophy.

Register

Cardiovascular Disease

Midwest CEPAC
September 26, 2019 10am - 4pm CT

University of Missouri-St. Louis
Century BC Room, Millennium Student Center
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC will convene to deliberate and vote on evidence presented in ICER's report on additive CVD therapies.


October 8, 2019

ICER will evaluate selected high-impact drugs with substantial price increases that occurred in the last quarter of 2018. ICER will review changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be significantly more beneficial for patients than what was previously understood. ICER will publish the final draft of its first UPI report in October 2019.


October 31, 2019 10am - 4pm PT

The California Endowment – Center for Healthy Communities Oakland
2000 Franklin Street
Oakland, CA 94612

CTAF will convene to review ICER's assessment of targeted immune modulators for rheumatoid arthritis.


Type 2 Diabetes

New England CEPAC
November 14, 2019 10am-4pm ET

Brown University
Providence, RI

The New England CEPAC will convene to deliberate on ICER's review of oral semaglutide for the treatment of type 2 diabetes.


December 18, 2019

In December 2019, ICER will issue an update to the framework that underpins our evidence reports on new drugs and other health care interventions. ICER's value framework is the product of more than 10 years' experience working with all participants in the health care system to develop methods to assess the comparative clinical effectiveness and the comparative value of health care tests, treatments, and delivery system innovations. The current iteration of the framework has guided ICER's assessments from 2017 to 2019.

To inform the planned update, ICER will open a national call for suggestions on how to improve our value assessment framework. Based on the feedback we receive, we plan to publish draft revisions to our value assessment framework on August 16th, welcome public comment on those proposed revisions through October 11th, and post our final updated framework on December 18th. This final framework will be applied to all assessments initiated in 2020 and beyond.


Acute Migraine

Midwest CEPAC
January 23, 2020 10am - 4pm CT

TBD – Chicago, IL

The Midwest CEPAC will convene to review ICER's assessment of acute migraine treatments.


past Meetings

Sep 2018
Midwest CEPAC

Amyloidosis

The Midwest CEPAC deliberated and voted on ICER's report on treatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council also reviewd a report on therapies for prostate cancer during this meeting.